ABOUT COMPANY
Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops new drugs for the treatment of neuropsychiatric and neurological diseases and other central nervous system (CNS) disorders in the United States. The company is headquartered in New York, New York.
|
EARNINGS
Gross Profit (TTM): -44864187
Market Capitalization: 4237721000
Operating Margin (TTM): -3.698
PE Ratio: None
PEG Ratio: 0
Profit Margin: 0
Revenue Per Share (TTM): 0.872
Revenue (TTM): 70586000
Quarterly Earnings Growth YOY: 0
Quarterly Revenue Growth YOY: 2.014
Trailing PE: -
|
DIVIDENDS
Diluted EPS (TTM): -3.2
Dividend Date: None
Dividend Per Share: None
Dividend Yield: 0%
EBITDA: -161484432
ExDividend Date: None
Forward Annual Dividend Rate:
Forward Annual Dividend Yield:
|